Levobupivacaina Altan (Levobupivacaine)

Levobupivacaine works by reversibly blocking voltage‑gated sodium channels on nerve membranes. This action stabilises the neuronal membrane in its inactive state, preventing the initiation and propagation of action potentials, which stops the transmission of pain signals from the site of injection to the central nervous system.

The dose of Levobupivacaina Altan is individualized and must be determined by the prescribing clinician. Dosing depends on factors such as the type of procedure, patient age, weight, comorbidities, and the specific route of administration. No fixed regimen is provided in public literature.

Safety data for levobupivacaine in pregnancy and lactation are limited. It should be used during pregnancy only when the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in small amounts in breast milk.

To place an order, submit an enquiry on the Levobupivacaina Altan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Levobupivacaina Altan is the S‑enantiomer of bupivacaine, offering a similar duration of action with a lower risk of cardiotoxicity and central nervous system toxicity. Compared with racemic bupivacaine, levobupivacaine provides comparable analgesic efficacy while improving the safety margin, especially in high‑dose or continuous infusion settings.

Levobupivacaina Altan should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the container. These conditions help maintain the stability and potency of the solution.

The product is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via epidural, infiltration, intrathecal, or peripheral nerve block techniques. The exact route, volume and concentration are selected based on the clinical indication and the patient’s individual needs.

Serious adverse events include systemic toxicity manifesting as seizures, cardiac arrhythmias, respiratory depression, prolonged motor block, and severe allergic reactions such as anaphylaxis. Early signs of toxicity—such as tinnitus, metallic taste, or visual disturbances—should prompt immediate medical evaluation and supportive care.

Levobupivacaina Altan is contraindicated in patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics. It should also be avoided in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or those receiving other agents that significantly increase the risk of local anesthetic systemic toxicity.